Sales of Novo Nordisk’s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or ...

Novo Nordisk said Thursday that the rampant growth of the U.S.' compounded drug industry was hurting Wegovy sales, and warned ...

Researchers assessed data from 16 million patients from 2006 to 2020 taking semaglutide-based drugs; the active ingredient in Wegovy.

Today was supposed to mark the beginning of the end for cheaper, knockoff versions of hot weight-loss drugs. The Food and Drug Administration wants bulk production of the copycats to stop ...

Yet federal regulators recently declared the blockbuster weight-loss drugs Wegovy and Zepbound are no longer in shortage. That means consumers who use telehealth companies or medical spas to get ...

Wegovy (semaglutide) and Mounjaro (tirzepatide) are brand-name injections. Wegovy is prescribed for weight loss and to lower cardiovascular risks. Mounjaro is approved for type 2 diabetes, and ...

The days of cheaper alternatives to popular weight-loss drugs like Wegovy and Zepbound are over for some Long Islanders and are numbered for others, pharmacists and compounding industry groups say.

Last year, around 200,000 prescriptions for copies of Novo Nordisk’s weight-loss drug Wegovy alone were being filled each month. But now, the makers of the original versions of the drugs say ...

Park is a senior health correspondent at TIME. Packets of Wegovy move along the line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on March 8, 2024. Packets of Wegovy move ...